Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021

Date: February 17, 2017
Pages: 160
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B716B1E86B3EN
Leaflet:

Download PDF Leaflet

Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021
The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021.

Increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for biomarker research are the major factors driving the growth of the global biomarkers market. In recent years, the Asian biomarkers market has witnessed significant growth due to the increasing use of biomarkers for diagnostic purposes, increasing incidence of chronic diseases, and increasing outsourcing of pharmaceutical R&D activities to outsourcing partners in Asia.

In this report, the global biomarkers market is segmented on the basis of product, type, application, disease indication, and region. On the basis of product, the biomarkers market is segmented into consumables, services, and software. The consumables segment is estimated to account for the largest share of the global biomarkers market in 2016. The large share can primarily be attributed to the lower price of consumables than that of screening and automation instruments.

On the basis of type, the biomarkers market is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers segment if further segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamic biomarkers, and prognostic biomarkers. The safety biomarkers segment is estimated to account for the largest share in 2016. This is due to their widespread applications in drug discovery and development.

On the basis of application, the biomarkers market is categorized into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications (DNA fingerprinting, ecotoxicology, and forensics). The diagnostics segment is estimated to account for the largest share of the market in 2016. Factors such as increasing prevalence of cancer, technologically developed biomarker products, individualized treatments for cancer, and the need for early-stage cancer diagnosis are driving the growth of this segment in the biomarkers market.

On the basis of disease indication, the biomarkers market is categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others (renal disorders, urinal diseases, diabetes, and tuberculosis). The cancer segment is estimated to account for the largest share of the biomarkers market in 2016. This is primarily attributed to the increasing prevalence of cancer. The use of cancer biomarkers provides great opportunities for improving the management of cancer patients by enhancing detection and efficacy of treatment.

New product launches was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs.

Research Coverage:

From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats), winning imperatives, and burning issues. The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives of governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to buy this report:

From an insight perspective, this research report focuses on various levels of analysis—industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the biomarkers market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on products offered by the top players in the biomarkers market
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for biomarker products across various regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the biomarkers market
  • Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the biomarkers market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
  2.2.1 KEY DATA FROM SECONDARY SOURCES
  2.2.2 KEY DATA FROM PRIMARY SOURCES
2.3 MARKET RANK ESTIMATION
2.4 KEY INDUSTRY INSIGHTS
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 BIOMARKERS: MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET, BY PRODUCT (2016)
4.3 BIOMARKERS MARKET, BY TYPE, 2016 VS. 2021
4.4 BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021
4.5 BIOMARKERS MARKET, BY DISEASE INDICATION, 2016 VS. 2021
4.6 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.7 LIFE CYCLE ANALYSIS, BY REGION, 2016

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Increasing diagnostic applications of biomarkers
      5.2.1.1.1 Personalized medicine
      5.2.1.1.2 Companion diagnostics
    5.2.1.2 Increasing R&D funding for pharma and biotech companies
    5.2.1.3 Increasing number of CROs and low cost of clinical trials in developing countries
    5.2.1.4 High prevalence of cancer
    5.2.1.5 New initiatives for biomarker research
  5.2.2 RESTRAINTS
    5.2.2.1 High capital investments and low cost-benefit ratio
    5.2.2.2 Poorly suited regulatory and reimbursement systems
    5.2.2.3 Technical issues related to sample collection and storage
  5.2.3 OPPORTUNITIES
    5.2.3.1 Emerging economies
  5.2.4 CHALLENGES
    5.2.4.1 Proving the clinical validity in biomarker-based tests

6 BIOMARKERS MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 CONSUMABLES
6.3 SERVICES
6.4 SOFTWARE

7 BIOMARKERS MARKET, BY TYPE

7.1 INTRODUCTION
7.2 SAFETY BIOMARKERS
7.3 EFFICACY BIOMARKERS
  7.3.1 PREDICTIVE BIOMARKERS
  7.3.2 SURROGATE BIOMARKERS
  7.3.3 PHARMACODYNAMIC BIOMARKERS
  7.3.4 PROGNOSTIC BIOMARKERS
7.4 VALIDATION BIOMARKERS

8 BIOMARKERS MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 DIAGNOSTICS
8.3 DRUG DISCOVERY AND DEVELOPMENT
8.4 PERSONALIZED MEDICINE
8.5 DISEASE RISK ASSESSMENT
8.6 OTHER APPLICATIONS

9 BIOMARKERS MARKET, BY DISEASE INDICATION

9.1 INTRODUCTION
9.2 CANCER
9.3 CARDIOVASCULAR DISORDERS
9.4 NEUROLOGICAL DISORDERS
9.5 IMMUNOLOGICAL DISORDERS
9.6 OTHER DISEASES

10 BIOMARKERS MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 U.S.
  10.2.2 CANADA
10.3 EUROPE
10.4 ASIA
  10.4.1 CHINA
  10.4.2 JAPAN
  10.4.3 REST OF ASIA
10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 COMPETITIVE SITUATION AND TRENDS
  11.2.1 PRODUCT LAUNCHES
  11.2.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS
  11.2.3 ACQUISITIONS
  11.2.4 OTHER DEVELOPMENTS
11.3 LEADING PLAYERS IN THE BIOMARKERS MARKET

12 COMPANY PROFILES

(Overview, Products and Services, Financials, Strategy & Development)*

12.1 QIAGEN N.V.
12.2 PERKINELMER, INC.
12.3 MERCK MILLIPORE
12.4 BIO-RAD LABORATORIES, INC.
12.5 ENZO BIOCHEM, INC.
12.6 EKF DIAGNOSTICS HOLDINGS, INC.
12.7 MESO SCALE DIAGNOSTICS, LLC.
12.8 BIOSIMS TECHNOLOGIES SAS
12.9 CISBIO BIOASSAYS
12.10 SIGNOSIS, INC.

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 OTHER DEVELOPMENTS
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.6 AVAILABLE CUSTOMIZATIONS
13.7 RELATED REPORTS
13.8 AUTHOR DETAILS

LIST OF TABLES

Table 1 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
Table 2 BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 3 BIOMARKER CONSUMABLES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 4 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 5 ASIA: BIOMARKER CONSUMABLES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 6 BIOMARKER SERVICES MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 7 NORTH AMERICA: BIOMARKER SERVICES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 8 ASIA: BIOMARKER SERVICES MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 9 BIOMARKER SOFTWARE MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 10 NORTH AMERICA: BIOMARKER SOFTWARE MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 11 ASIA: BIOMARKER SOFTWARE MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 12 BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 13 SAFETY BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 14 NORTH AMERICA: SAFETY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 15 ASIA: SAFETY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 16 EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 17 EFFICACY BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 18 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 19 ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 20 PREDICTIVE BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 21 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 22 SURROGATE BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 23 NORTH AMERICA: SURROGATE BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 24 PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 25 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 26 PROGNOSTIC BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 27 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 28 VALIDATION BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 29 NORTH AMERICA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 30 ASIA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 31 BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 32 BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY REGION, 2014–2021 (USD BILLION)
Table 33 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY COUNTRY, 2014–2021 (USD BILLION)
Table 34 ASIA: BIOMARKERS MARKET SIZE FOR DIAGNOSTICS DEVELOPMENT, BY COUNTRY, 2014–2021 (USD BILLION)
Table 35 BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2014–2021 (USD BILLION)
Table 36 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2014–2021 (USD BILLION)
Table 37 ASIA: BIOMARKERS MARKET SIZE FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2014–2021 (USD BILLION)
Table 38 BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY REGION, 2014–2021 (USD BILLION)
Table 39 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 40 ASIA: BIOMARKERS MARKET SIZE FOR PERSONALIZED MEDICINE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 41 BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY REGION, 2014–2021 (USD BILLION)
Table 42 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2014–2021 (USD BILLION)
Table 43 ASIA: BIOMARKERS MARKET SIZE FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2014–2021 (USD BILLION)
Table 44 BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014–2021 (USD BILLION)
Table 45 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 46 ASIA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 47 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 48 KEY CANCER BIOMARKERS IN CLINICAL USE
Table 49 BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2014–2021 (USD BILLION)
Table 50 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CANCER, BY COUNTRY, 2014–2021 (USD BILLION)
Table 51 ASIA: BIOMARKERS MARKET SIZE FOR CANCER, BY COUNTRY, 2014–2021 (USD BILLION)
Table 52 BIOMARKERS FOR CARDIOVASCULAR DISORDER
Table 53 BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2014–2021 (USD BILLION)
Table 54 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 55 ASIA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION/COUNTRY, 2014–2021 (USD BILLION)
Table 56 BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2014–2021 (USD BILLION)
Table 57 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 58 ASIA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION/COUNTRY, 2014–2021 (USD BILLION)
Table 59 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
Table 60 BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2014–2021 (USD BILLION)
Table 61 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2014–2021 (USD BILLION)
Table 62 ASIA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION/COUNTRY, 2014–2021 (USD BILLION)
Table 63 BIOMARKERS FOR RENAL DISORDERS
Table 64 BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY REGION, 2014–2021 (USD BILLION)
Table 65 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY COUNTRY, 2014–2021 (USD BILLION)
Table 66 ASIA: BIOMARKERS MARKET SIZE FOR OTHER DISEASES, BY COUNTRY, 2014–2021 (USD BILLION)
Table 67 BIOMARKERS MARKET SIZE, BY REGION, 2014–2021 (USD BILLION)
Table 68 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 69 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 70 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 71 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 72 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 73 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 74 U.S.: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 75 U.S.: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 76 U.S.: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 77 U.S.: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 78 U.S.: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 79 CANADA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 80 CANADA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 81 CANADA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 82 CANADA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 83 CANADA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 84 EUROPE: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 85 EUROPE: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 86 EUROPE: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 87 EUROPE: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 88 EUROPE: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 89 ASIA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2014–2021 (USD BILLION)
Table 90 ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 91 ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 92 ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 93 ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 94 ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 95 CHINA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 96 CHINA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 97 CHINA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 98 CHINA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 99 JAPAN: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 100 JAPAN: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 101 JAPAN: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 102 JAPAN: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 103 REST OF ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 104 REST OF ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 105 REST OF ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 106 REST OF ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 107 ROW: BIOMARKERS MARKET SIZE, BY PRODUCT, 2014–2021 (USD BILLION)
Table 108 ROW: BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 109 ROW: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2014–2021 (USD BILLION)
Table 110 ROW: BIOMARKERS MARKET SIZE, BY APPLICATION, 2014–2021 (USD BILLION)
Table 111 ROW: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2014–2021 (USD BILLION)
Table 112 BATTLE FOR MARKET SHARE: PRODUCT LAUNCH WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS IN BIOMARKERS MARKET BETWEEN 2014 AND 2016
Table 113 PRODUCT LAUNCHES, 2014–2016
Table 114 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS, 2014–2016
Table 115 ACQUISITIONS, 2014–2016
Table 116 OTHER DEVELOPMENTS, 2014–2016
Table 117 RANK OF COMPANIES IN THE BIOMARKERS MARKET, 2016

LIST OF FIGURES

Figure 1 BIOMARKERS MARKET SEGMENTATION
Figure 2 RESEARCH DESIGN
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 BIOMARKERS MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD BILLION)
Figure 8 BIOMARKERS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD BILLION)
Figure 9 BIOMARKERS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD BILLION)
Figure 10 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2016 VS. 2021 (USD BILLION)
Figure 11 BIOMARKERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD BILLION)
Figure 12 BIOMARKERS MARKET TO REGISTER A HIGH, DOUBLE-DIGIT GROWTH RATE DURING THE FORECAST PERIOD
Figure 13 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
Figure 14 SAFETY BIOMARKERS WILL CONTINUE TO DOMINATE THE BIOMARKERS MARKET IN 2021
Figure 15 DIAGNOSTICS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
Figure 16 CANCER SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2016
Figure 17 ASIA TO ACCOUNT FOR THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 18 ASIAN MARKET SHOWS LUCRATIVE GROWTH OPPORTUNITIES
Figure 19 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 20 INCREASING R&D INVESTMENTS BOOSTING GROWTH IN THE BIOMARKERS MARKET
Figure 21 INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE (2012 VS. 2015 VS. 2020)
Figure 22 CONSUMABLES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2016
Figure 23 SAFETY BIOMARKERS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
Figure 24 DIAGNOSTICS APPLICATION SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2016
Figure 25 CANCER TO FORM THE LARGEST SEGMENT IN THE BIOMARKERS MARKET IN 2016
Figure 26 BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT
Figure 27 ASIA: AN ATTRACTIVE DESTINATION FOR ALL APPLICATION CATEGORIES
Figure 28 NORTH AMERICA: MARKET SNAPSHOT
Figure 29 ASIA: MARKET SNAPSHOT
Figure 30 PRODUCT LAUNCH, THE MOST ADOPTED GROWTH STRATEGY FROM 2014 TO 2016
Figure 31 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS (2015)
Figure 32 COMPANY SNAPSHOT: QIAGEN N.V. (2015)
Figure 33 COMPANY SNAPSHOT: PERKINELMER, INC. (2015)
Figure 34 COMPANY SNAPSHOT: MERCK MILLIPORE (2015)
Figure 35 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2015)
Figure 36 COMPANY SNAPSHOT: ENZO BIOCHEM, INC. (2016)
Figure 37 COMPANY SNAPSHOT: EKF DIAGNOSTICS HOLDINGS, INC. (2015)
Skip to top


Ask Your Question

Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: